In GPR119‐deficient NAFPD mice, terazosin failed to induce the beneficial effects observed in regular NAFPD mice, including improvements in obesity, hyperglycemia, and insulin sensitivity, as well as the increase of β‐cell functional gene expression in the pancreas. The gene discussed is GPR119; the disease is Obesity.